25

May

2023

|

13:59 PM

Europe/Amsterdam

Not intended for U.S. and UK Media

Summary

Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride data in metastatic castration-resistant prostate cancer (mCRPC) / Confirming Bayer’s investment in Precision Oncology, larotrectinib data presented at ASCO demonstrate long-term efficacy and safety in patients with tropomyosin receptor kinase (TRK) fusion lung and thyroid cancer, in addition to data from investigator-initiated research in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS)